Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Lauren Pommert, MDMS, Deepa Bhojwani, MD, Richard Sposto, PhD, Ellynore Florendo, Eric Schafer, MD, Nathan Gossai, MD, Van Thu Huynh, MD, Sridhar Rao, MD PhD, Michael J. Burke, MD

Blood (2019) 134 (Supplement_1): 1325.

https://doi.org/10.1182/blood-2019-127298

Published: 2019

Journal Articles

A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium

Weili Sun, Timothy Triche, Jr, Jemily Malvar, Paul Gaynon, Richard Sposto, Xiaojing Yang, Henrique Bittencourt, Andrew E. Place, Yoav Messinger, Chris Fraser, Luciano Dalla-Pozza, Bodour Salhia, Peter Jones, Alan S. Wayne, Lia Gore, Todd M. Cooper, Gangning Liang

Blood (2018) 131 (10): 1145–1148.

https://doi.org/10.1182/blood-2017-09-803809

Published: 2018

Includes: Supplemental data

Journal Articles

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Michael J. Burke, MD, Patrick Brown, MD, Richard Sposto, PhD, Lia Gore, MD, Alan S. Wayne, MD

Blood (2016) 128 (22): 2781.

https://doi.org/10.1182/blood.V128.22.2781.2781

Published: 2016

Journal Articles

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

Weili Sun, MDPhD, Jemily Malvar, MS, Richard Sposto, PhD, Anupam Verma, MD, Jennifer J. Wilkes, MD, Robyn M. Dennis, MD, Kenneth Matthew Heym, MD, Elena Eckroth, CCRC, Jeannette Vandergiesse, BA, CCRP, Paul S. Gaynon, MD, Alan S. Wayne, MD, James A. Whitlock, MD

Blood (2015) 126 (23): 3760.

https://doi.org/10.1182/blood.V126.23.3760.3760

Published: 2015

Journal Articles

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

Weili Sun, MDPhD, Alison Marie Smith, BS, Orgal Etan, MD, Richard Sposto, PhD, Jennifer J. Wilkes, MD, Rebecca A Gardner, MD, Hur Minjun, Vanessa Pineros, Emily Olson, MD, Yijuin Tan, Susan R. Rheingold, MD, Michael J. Burke, MD, Alan S. Wayne, MD

Blood (2014) 124 (21): 3647.

https://doi.org/10.1182/blood.V124.21.3647.3647

Published: 2014

Journal Articles

Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Michael J. Burke, MD, Patrick Brown, MD, Lia Gore, MD, Richard Sposto, PhD, Deepa Bhojwani, Bill H Chang, MD PhD, Steven G. Dubois, MD, Paul S Gaynon, MD, Julia Glade-Bender, MD, Kenneth Matthew Heym, MD, Maria Luisa Sulis, MD, Jessica A. Pollard, MD, Anupam Verma, MD, Van Huynh, MD

Blood (2014) 124 (21): 3650.

https://doi.org/10.1182/blood.V124.21.3650.3650

Published: 2014

Journal Articles

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Blood (2014) 124 (21): 795.

https://doi.org/10.1182/blood.V124.21.795.795

Published: 2014

Journal Articles

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Weili Sun, MDPhD, Paul S Gaynon, MD, Richard Sposto, PhD, Henrique Bittencourt, MD, Andrew E. Place, MDPhD, Yoav H Messinger, MD, Chris Fraser, MD, Luciano Dalla-Pozza, MD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Xiaojing Yang, PhD, Gangning Liang, PhD, Peter A. Jones, PhD DSc, Alan S. Wayne, MD, Todd Cooper, DO

Blood (2014) 124 (21): 3764.

https://doi.org/10.1182/blood.V124.21.3764.3764

Published: 2014

Journal Articles

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Blood (2014) 124 (21): 3705.

https://doi.org/10.1182/blood.V124.21.3705.3705

Published: 2014

Journal Articles

Novel Proteasome Inhibitors Induce Mitochondrial Destabilization and Activate Caspase Mediated Apoptosis In Preclinical Models Of Pediatric B-Cell Cancers

Aneel Paulus, MD, MS, Kasyapa S. Chitta, PhD, Eric Sandler, MD, Sharoon Akhtar, Maja Kuranz, Han Tun, MD, Vivek Roy, M.D., James M. Foran, MD, Kena Miller, A.R.N.P, Candido E. Rivera, MD, Asher Chanan-Khan, MD

Blood (2013) 122 (21): 5140.

https://doi.org/10.1182/blood.V122.21.5140.5140

Published: 2013

Journal Articles

Results Of a Phase I Study Of Clofarabine and 2 Gy Total Body Irradiation (TBI) As a Non-Myeloablative Preparative Regimen For Hematopoietic Stem Cell Transplantation (HSCT) In High Risk Children With Hematologic Malignancies: A Multi-Center TACL Study

Sandeep Soni, MD, Hisham Abdel-Azim, MD, Elena Eckroth, CCRC, Jeanette van der Geissen, BA, CCRP, Meghann Pine McManus, DO, MPH, Eneida R. Nemecek, MD, Richard Sposto, PhD, Blythe Thompson, MD, Ann E Woolfrey, MD, Haydar A Frangoul, MD

Blood (2013) 122 (21): 3286.

https://doi.org/10.1182/blood.V122.21.3286.3286

Published: 2013

Journal Articles

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

Todd Michael Cooper, Jemily Malvar, M.S., Jeannette Cassar, Elena Eckroth, CCRC, Richard Sposto, PhD, Paul Gaynon, MD, Steven Dubois, MD, Lia Gore, MD, Margaret E. Macy, M.D., Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Javier Oesterheld, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2013) 122 (21): 624.

https://doi.org/10.1182/blood.V122.21.624.624

Published: 2013

Journal Articles

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Todd Cooper, DO, Richard Sposto, PhD, Jeannette Cassar, Elena Eckroth, CCRC, Jemily Malvar, M.S., Paul Gaynon, MD, Steven Dubois, MD, Bill H Chang, MD, PhD, Lia Gore, MD, Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2012) 120 (21): 3605.

https://doi.org/10.1182/blood.V120.21.3605.3605

Published: 2012

Journal Articles

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Yoav H. Messinger, Paul S. Gaynon, Richard Sposto, Jeannette van der Giessen, Elena Eckroth, Jemily Malvar, Bruce C. Bostrom

Blood (2012) 120 (2): 285–290.

https://doi.org/10.1182/blood-2012-04-418640

Published: 2012

Includes: Supplemental data

Journal Articles

Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study

Yoav H Messinger, MD, Paul Gaynon, MD, Richard Sposto, Ph.D., Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Jemily Malvar, M.S., Bruce C. Bostrom, MD

Blood (2011) 118 (21): 251.

https://doi.org/10.1182/blood.V118.21.251.251

Published: 2011

Journal Articles

Therapeutic Potential for Toll-Like Receptor 2 Agonists In Pediatric Acute Lymphoblastic Leukemia (pre-B ALL): Induction of Apoptosis and Anti-ALL Immunogenicity

Nina Rolf, MD, Amina Kariminia, PhD, Sabine Ivison, PhD, Kirk R. Schultz, MD

Blood (2010) 116 (21): 870.

https://doi.org/10.1182/blood.V116.21.870.870

Published: 2010

Journal Articles

Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Yoav H. Messinger, MD, Paul S. Gaynon, MD, Elizabeth Raetz, MD, Raymond Hutchinson, MD, MS, Steven DuBois, MD, Julia Glade Bender, MD, Richard Sposto, PhD, Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Bruce C. Bostrom, MD

Blood (2008) 112 (11): 1919.

https://doi.org/10.1182/blood.V112.11.1919.1919

Published: 2008

Journal Articles

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Richard H. Ko, MD, Lingyun Ji, MS, Richard Sposto, PhD, Phillip Barnette, MD, Bruce Bostrom, MD, Raymond Hutchinson, MD, Elizabeth Raetz, MD, Nita Seibel, MD, Clare Twist, MD, Elena Eckroth, BA, Paul Gaynon, MD, Mignon Loh, MD

Blood (2007) 110 (11): 854.

https://doi.org/10.1182/blood.V110.11.854.854

Published: 2007

NARROW

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events

Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia

Novel Proteasome Inhibitors Induce Mitochondrial Destabilization and Activate Caspase Mediated Apoptosis In Preclinical Models Of Pediatric B-Cell Cancers

Results Of a Phase I Study Of Clofarabine and 2 Gy Total Body Irradiation (TBI) As a Non-Myeloablative Preparative Regimen For Hematopoietic Stem Cell Transplantation (HSCT) In High Risk Children With Hematologic Malignancies: A Multi-Center TACL Study

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study

Therapeutic Potential for Toll-Like Receptor 2 Agonists In Pediatric Acute Lymphoblastic Leukemia (pre-B ALL): Induction of Apoptosis and Anti-ALL Immunogenicity

Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only